Aviragen Therapeutics (AVIR) Misses Q4 EPS by 13c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.57), $0.13 worse than the analyst estimate of ($0.44).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Hawaiian Electric trades at 8.8x P/E, but wildfire risk clouds value case
• Can-Am to provide $150,000 and vehicles to Farm Rescue over three years
• Five Below (FIVE) call put ratio 1 call to 1.3 puts into quarter results